Trial Profile
A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Idarubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 23 Apr 2020 Status changed from active, no longer recruiting to completed.
- 11 Aug 2019 Planned End Date changed from 1 Oct 2019 to 1 Feb 2020.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology